Viatris and biocon biologics announce launch of interchangeable semglee® (insulin glargine-yfgn) injection and insulin glargine (insulin glargine-yfgn) injection

Pittsburgh and bengaluru, india, nov. 16, 2021 /prnewswire/ -- viatris inc. (nasdaq: vtrs) and biocon biologics ltd. today announced the u.s. launch of interchangeable biosimilars semglee® (insulin glargine-yfgn) injection, a branded product, and insulin glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
VTRS Ratings Summary
VTRS Quant Ranking